Table 1.
Baseline characteristics of the study population (n = 127)
| No biliary candidiasis (n = 89) | Biliary candidiasis (n = 38) | P value | |
| Age (mean ± SD), yr | 58.3 ± 15.6 | 64.7 ± 15.0 | < 0.05 |
| Male/female | 52/37 | 20/18 | NS |
| Primary diagnosis | NS | ||
| Suspected carcinoma of the biliary tract | 16 (18.0) | 10 (26.3) | |
| Stenosing papillitis | 11 (12.4) | 3 (7.9) | |
| Carcinoma | 9 (10.1) | 6 (15.8) | |
| PSC | 9 (10.1) | 5 (13.2) | |
| CBD stenosis of unknown origin | 13 (14.6) | 5 (13.2) | |
| Choledocholithiasis | 9 (10.1) | 3 (7.9) | |
| Cholestatic hepatitis | 4 (4.5) | 1 (2.6) | |
| Pancreatitis | 4 (4.5) | - | |
| Other | 14 (15.7) | 5 (13.2) | |
| Indication for ERCP | NS | ||
| CBD stenosis | 18 (20.2) | 10 (26.3) | |
| Suspected carcinoma | 15 (16.9) | 8 (21.1) | |
| Carcinoma | 9 (10.1) | 6 (15.8) | |
| Cholestasis | 9 (10.1) | 3 (7.9) | |
| Choledocholithiasis | 8 (9.0) | 1 (2.6) | |
| Cholangitis | 7 (7.9) | 2 (5.3) | |
| PSC | 6 (6.7) | 5 (13.2) | |
| Papillitis stenosans | 4 (4.5) | - | |
| Pancreatitis | 2 (2.2) | - | |
| Cholestatic hepatitis | 1 (1.1) | 1 (2.6) | |
| Other | 10 (11.2) | 2 (5.3) |
ERCP: Endoscopic retrograde cholangiopancreatography; CBD: Common bile duct; NS: Not significant; PSC: Primary sclerosing cholangitis; Other: Ischemic type biliary lesions, stenosis of the biliary anastomosis after liver transplantation, biliary cast syndrome, retroperitoneal fibrosis, iatrogenic injury of the bile duct, suspected primary or secondary sclerosing cholangitis.